Evolus, Inc. (NASDAQ:EOLS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Evolus, Inc. (NASDAQ:EOLS) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $20.80.

Several brokerages have issued reports on EOLS. Needham & Company LLC restated a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Wall Street Zen upgraded Evolus from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Mizuho reduced their target price on Evolus from $20.00 to $19.00 and set an “outperform” rating on the stock in a research note on Monday, December 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Evolus in a research report on Friday.

Evolus Stock Down 1.6%

EOLS stock opened at $5.65 on Friday. Evolus has a twelve month low of $5.13 and a twelve month high of $17.12. The stock has a market capitalization of $366.23 million, a price-to-earnings ratio of -6.14 and a beta of 0.91. The firm’s fifty day simple moving average is $6.80 and its two-hundred day simple moving average is $7.29.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $68.97 million for the quarter, compared to analysts’ expectations of $91.23 million. As a group, equities research analysts expect that Evolus will post -0.61 EPS for the current year.

Insiders Place Their Bets

In other Evolus news, insider David Moatazedi sold 10,539 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the completion of the sale, the insider directly owned 354,388 shares of the company’s stock, valued at $2,533,874.20. The trade was a 2.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new stake in shares of Evolus during the 4th quarter worth $185,000. Krensavage Asset Management LLC bought a new position in Evolus in the third quarter worth about $614,000. Woodline Partners LP lifted its position in shares of Evolus by 92.2% during the third quarter. Woodline Partners LP now owns 393,222 shares of the company’s stock valued at $2,414,000 after buying an additional 188,660 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Evolus by 71.0% in the 3rd quarter. XTX Topco Ltd now owns 140,773 shares of the company’s stock valued at $864,000 after buying an additional 58,426 shares in the last quarter. Finally, Wexford Capital LP bought a new stake in shares of Evolus in the 3rd quarter valued at about $37,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.